For the first time in U.S. history, cannabinoid products are being deployed inside a federally aligned healthcare model—delivered directly to patients by physicians and measured against clinical outcomes.
This is not a policy discussion. It is an operational program.
RELATED: Medical cannabis for seniors: a doctor explains what to know
The Substance Access Beneficiary Engagement Incentive (BEI), launched in April 2026 within Medicare’s ACO REACH model and the Enhancing Oncology Model (EOM), establishes the first federally sanctioned pathway for cannabinoids inside the U.S. healthcare system. Roughly 100 organizations and more than 125,000 providers are eligible to participate, representing millions of attributed patients managed under value-based care.
The program is live—but participation is not automatic. Each Accountable Care Organization must elect to participate and submit an Implementation Plan outlining how it will deploy qualifying products, meet program requirements, and track outcomes within its patient population.
In 2027, the program expands into the ACO LEAD model, extending this framework across a broader national footprint and into a significantly larger patient population under Medicare’s next-generation value-based care infrastructure. This is the first phase of a system already built to scale.
A Clinical Channel, Not a Retail One
BEI does not function like a traditional Medicare benefit. There is no reimbursement claim, no pharmacy routing, and no patient copay.
Participating ACOs purchase qualifying cannabinoid products at fair market value and provide them directly to patients—up to $500 per patient per year. When outcomes improve and the total cost of care declines, the ACO shares in the savings.
This operates as a clinical supply channel—products move through physician workflows and are evaluated as interventions tied directly to cost reduction. That evaluation only occurs inside ACOs that have elected to participate and built the infrastructure to support it.
Access Is the Constraint
The defining constraint in this market is not awareness or demand.
It is access.
RELATED: Ozempic and cannabis: what happens when you use both
Access is established at the ACO level through Implementation Plans and ongoing program requirements that must withstand regulatory scrutiny. For a cannabinoid product to be deployed, it must be specified, documented, and supported within that structure, including product definition, safety and quality data, physician oversight, patient screening, and outcomes tracking.
This is the operational layer that determines whether a product can be used at all. The first phase of this market is defined by who can qualify to participate.
Where the Advantage Is Built
Once access is established, adoption follows.
Physicians determine whether a product is used in care, but only within systems that have already defined what is available to them. This is a clinical channel, and clinical channels reward preparation.
The companies positioned to succeed are those already built for this environment: human clinical data, real-world evidence infrastructure, established safety profiles, and manufacturing standards that meet regulatory expectations.
Most of the category is not built this way. A small number of companies are.
That gap will define the market.
How It Shows Up in Care
Sleep provides a clear way to understand how this model works in practice.
A patient in her seventies has been on sedative-hypnotics for years. Her physician understands the long-term risks—falls, cognitive decline, dependency—but has lacked a credible alternative.
RELATED: CBD shows promise for Alzheimer’s in early study
Within a participating ACO, that physician can introduce a cannabinoid-based intervention supported by clinical data, provide it directly to the patient, and track outcomes over time.
As the patient reduces reliance on higher-risk sleep medications and improves sleep quality, downstream health risks decline. This is exactly the type of intervention the ACO model is designed to reward.
Aligned Incentives, Measurable Impact
This is not a discretionary model. ACOs are financially incentivized to deploy interventions that improve outcomes and reduce the total cost of care.
Real-world data already points in this direction. In insomnia populations, cannabinoid-based interventions have been associated with meaningful reductions in sleep medication use—approximately 26.7 percent overall, with reductions approaching 50 percent for benzodiazepines and 60 percent among patients over 65.
At a broader level, large-scale evidence reviews show positive benefit-over-risk margins across pain, nausea, appetite, inflammation, and quality of life, alongside reduced reliance on higher-risk medications.
These improvements map directly to the cost drivers ACOs are measured against: emergency utilization, polypharmacy, and preventable escalation of care.
You do not need full replacement of existing therapies to generate impact. Partial substitution across a large patient population is sufficient—and the data already support that direction.
From Participation to Scale
BEI establishes the initial deployment within ACO REACH and EOM. The transition into ACO LEAD extends this framework into a broader, long-term model designed to operate through 2036.
As more ACOs elect to participate and build compliant Implementation Plans, the footprint expands. As outcomes are generated, physician adoption deepens.
RELATED: You can get a medical cannabis card in a day—here’s how
This is how cannabinoids begin to take shape as a standardized component of outcome-driven care.
The BEI program is the first federally sanctioned deployment of cannabinoids inside the U.S. healthcare system, with a defined path into larger value-based care models beginning in 2027. The program is live, but participation is defined at the ACO level—through Implementation Plans, operational readiness, and ongoing program requirements. Adoption is driven by physicians, and expansion follows performance. The system is already in motion—the only open question is which companies are prepared to operate inside it and define what comes next.
*This article was submitted by an unpaid guest contributor. The opinions or statements within do not necessarily reflect those of GreenState or HNP. The author is solely responsible for the content.